Skip to main content
. 2007 Jan 8;150(4):480–487. doi: 10.1038/sj.bjp.0707000

Table 1.

In vitro transactivation activity profile of rosiglitazone and muraglitazar

Compound Transactivation Ec50 (μM)
  hPPARγ hPPARα hPPARδ
Rosiglitazone (BRL 49653) 0.056±0.017 >30 >30
Muraglitazar (BMS 298585) 0.16±0.04 0.28±0.03 >30

EC50 values for PPARα, γ or δ agonist activity were calculated as the concentration of the test ligand (μM) required for the half-maximal fold induction of luciferase activity. Data shown are means±s.e.m. from three experiments for each treatment.